TaiMed Biologics Inc. (TPEX:4147)

Market Cap	25.61B
Revenue (ttm)	610.16M
Net Income (ttm)	-201.83M
Shares Out	273.08M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,486,476
Average Volume	2,060,762
Open	92.10
Previous Close	93.80
Day's Range	88.00 - 92.30
52-Week Range	66.60 - 108.50
Beta	0.43
RSI	47.41
Earnings Date	Mar 25, 2025

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antib...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4147

Financial Performance

In 2024, TaiMed Biologics's revenue was 610.16 million, an increase of 24.07% compared to the previous year's 491.78 million. Losses were -201.83 million, 3.60% more than in 2023.